Tesamorelin 10mg Pen
R 1,400.00
Skip to product information
Tesamorelin 10mg Pen
R 1,400.00
Understanding Tesamorelin: The Visceral Fat Reduction Solution
Product Strength: 2mg / 6mg per vial (commonly reconstituted with Bacteriostatic Water or provided in multi-dose delivery systems)
Storage: Prior to reconstitution, store lyophilized powder in the refrigerator between 2–8 °C or at controlled room temperature up to 25 °C. After reconstitution, keep refrigerated between 2–8 °C and use within the manufacturer's specified timeframe (typically 24 hours to 14 days depending on the formulation) to maintain potency and stability. Protect from light.
What It Is
Tesamorelin (as tesamorelin acetate) is a synthetic peptide consisting of 44 amino acids. It is a stabilized analogue of Growth Hormone-Releasing Hormone (GHRH), modified with an anchoring hexenoyl group at its N-terminal tyrosine to enhance its stability, metabolic half-life, and resistance to enzymatic degradation compared to natural GHRH.
The clinical development of Tesamorelin stemmed from the critical need to address metabolic complications observed in HIV-infected patients undergoing highly active antiretroviral therapy (HAART). In November 2010, the U.S. Food and Drug Administration (FDA) approved tesamorelin under the brand name Egrifta® to reduce excess abdominal fat in HIV-infected patients with lipodystrophy.
Mechanism of Action
Tesamorelin functions as a selective agonist at growth hormone-releasing hormone receptors (GHRHR) in the anterior pituitary gland. Unlike recombinant human growth hormone (rhGH), which causes unnatural, pulsatile-shattering spikes in systemic GH, Tesamorelin stimulates the pituitary to secrete growth hormone in a more physiological, pulsatile manner.
Once released, growth hormone travels to the liver and peripheral tissues to stimulate the synthesis and secretion of Insulin-like Growth Factor 1 (IGF-1). The combined elevation of GH and IGF-1 drives downstream lipolytic pathways. GH binds directly to adipocytes, activating hormone-sensitive lipase (HSL) and promoting lipolysis—the breakdown of stored triglycerides into free fatty acids. This effect is exceptionally pronounced in visceral adipose tissue (VAT), which possesses a higher density of GHRH receptors and a greater sensitivity to lipolytic stimuli compared to subcutaneous fat.
Key Research Applications & Uses
FDA-Approved Indication:
- HIV-Associated Lipodystrophy: Tesamorelin is specifically indicated for the reduction of excess visceral abdominal fat in HIV-infected patients suffering from lipodystrophy. Visceral fat is the deep, dangerous fat surrounding internal organs that increases cardiovascular and metabolic risks.
Off-Label & Research Uses:
- Non-HIV Visceral Adiposity: It is studied for its ability to target deep, stubborn abdominal fat in individuals without HIV who suffer from metabolic syndrome or severe central obesity.
- Non-Alcoholic Fatty Liver Disease (NAFLD/NASH): Clinical studies have demonstrated that Tesamorelin significantly reduces liver fat content, offering a potential therapeutic avenue for reversing early-stage fatty liver disease.
- Age-Related Growth Hormone Decline: The peptide is evaluated in anti-aging and regenerative medicine protocols to naturally restore declining growth hormone levels in older adults.
- Cognitive Optimization: Early clinical research suggests that GHRH analogues may improve executive function and mild cognitive impairment in older individuals by enhancing cerebral blood flow and neuroprotection.
- Lean Body Mass Preservation: Due to the anabolic nature of elevated growth hormone and IGF-1, research explores its capacity to support lean muscle maintenance during targeted fat loss phases.
Administration & Dosage
Tesamorelin is administered via subcutaneous injection, usually into the abdominal region, avoiding scar tissue, bruising, or the navel.
- Timing: Administered once daily, typically in the morning or before bedtime on an empty stomach to optimize natural growth hormone secretion patterns.
- Frequency: Standard clinical dosing for approved indications is a daily subcutaneous injection. Continuous monitoring of IGF-1 levels is recommended during long-term therapy.
Onset & Duration:
- Onset: Changes in systemic growth hormone levels occur rapidly within hours of injection. However, visible reductions in visceral fat require consistent daily compliance.
- Duration: Noticeable improvements in body composition typically present within 12 to 26 weeks of continuous therapy. Visceral fat accumulation generally recurs if the medication is discontinued.
Contraindications & Precautions
Tesamorelin is contraindicated in individuals with the following conditions:
- Active Malignancy or Cancer History: Growth hormone and IGF-1 promote cellular proliferation. Any active malignancy or history of cancer is a strict contraindication.
- Pregnancy and Lactation: Tesamorelin can cause fetal harm and is contraindicated during pregnancy. It should be discontinued immediately if pregnancy occurs.
- Disruption of the Hypothalamic-Pituitary Axis: Patients with pituitary tumors, hypophysectomy, or intracranial radiation therapy should not use this peptide.
- Hypersensitivity: Known allergy to tesamorelin, mannitol, or any structural component of the injection formulation.
Adverse Reactions & Side Effects
The most common side effects associated with Tesamorelin are generally mild to moderate, primarily related to increased growth hormone levels and fluid retention:
- Arthralgia and Myalgia: Joint pain and muscle aches occur in roughly 13–14% of users due to fluid shifts in tissue space.
- Injection Site Reactions: Redness, swelling, itching, or pain at the site of injection, affecting up to 12% of users.
- Peripheral Edema: Swelling in the hands, feet, or lower legs caused by mild fluid retention.
- Paresthesia and Carpal Tunnel Symptoms: Numbness, tingling, or stiffness in fingers and extremities.
- Glucose Intolerance: Transient increases in blood sugar or HbA1c can occur; growth hormone naturally antagonizes insulin action.
- Nausea and Dyspepsia: Mild digestive discomfort.
- Headache: Mild to moderate, typically resolving as the body adjusts.
Long-Term or Rare Side Effects:
- Excessive IGF-1 Elevation: Prolonged, unmonitored therapy may push IGF-1 levels beyond normal physiological ranges, increasing the risk of acromegaly-like symptoms or systemic insulin resistance.
- Development of Anti-Drug Antibodies: A small percentage of long-term users may develop antibodies to the peptide, which can reduce its clinical efficacy over time.
Disclaimer:
This information is for general knowledge and educational purposes only and does not constitute medical advice. Always consult with a qualified medical professional regarding any cosmetic or medical procedure.
This information is for general knowledge and educational purposes only and does not constitute medical advice. Always consult with a qualified medical professional regarding any cosmetic or medical procedure.